Compare Stocks → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNYSE:AMT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.49-0.3%$7.87$2.09▼$14.84$531.06M0.224.75 million shs2.67 million shsAMTAmerican Tower$197.00+0.6%$184.67$154.58▼$219.10$92.00B0.792.46 million shs2.33 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+2.46%+2.88%-32.04%+76.29%AMTAmerican Tower0.00%+5.28%+7.69%-5.05%+2.40%Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune0.887 of 5 stars3.31.00.00.01.81.70.0AMTAmerican Tower4.6774 of 5 stars3.53.01.73.12.82.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.60Moderate Buy$17.25130.31% UpsideAMTAmerican Tower2.91Moderate Buy$220.9112.14% UpsideCurrent Analyst RatingsLatest UCM, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$234.00 ➝ $223.005/14/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/10/2024ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $24.005/1/2024AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$243.00 ➝ $223.005/1/2024AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$228.00 ➝ $220.005/1/2024AMTAmerican TowerRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$226.00 ➝ $248.004/29/2024ALTAltimmuneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/15/2024AMTAmerican TowerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$183.00 ➝ $196.004/8/2024AMTAmerican TowerMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$205.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$410K1,295.26N/AN/A$2.75 per share2.72AMTAmerican Tower$11.14B8.25$9.97 per share19.76$23.30 per share8.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.59N/AN/AN/A-22,645.37%-46.96%-42.96%8/8/2024 (Estimated)AMTAmerican Tower$1.48B$4.4244.5719.141.4018.42%18.45%3.11%7/25/2024 (Estimated)Latest UCM, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024ALTAltimmune-$0.36-$0.34+$0.02-$0.34N/A$0.01 million 4/30/2024Q1 2024AMTAmerican Tower$2.43$1.96-$0.47$1.96$2.79 billion$2.83 billion 3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.483.29%+12.50%146.61%N/ALatest UCM, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/23/2024AMTAmerican Towerquarterly$1.623.47%6/14/20246/14/20247/12/20243/14/2024AMTAmerican Towerquarterly$1.623.3%4/11/20244/12/20244/26/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.5516.55AMTAmerican Tower3.390.850.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.18%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.90 million68.00 millionOptionableAMTAmerican Tower5,643466.98 million466.13 millionOptionableUCM, ADR, AMT, and ALT HeadlinesRecent News About These CompaniesJune 3 at 5:31 PM | marketbeat.comCIBC Asset Management Inc Reduces Position in American Tower Co. (NYSE:AMT)June 2 at 1:56 PM | marketbeat.comBristol Gate Capital Partners Inc. Has $86.30 Million Stake in American Tower Co. (NYSE:AMT)June 1 at 9:41 PM | marketbeat.comEagle Asset Management Inc. Decreases Stake in American Tower Co. (NYSE:AMT)May 31 at 8:18 PM | marketbeat.comOtter Creek Advisors LLC Takes Position in American Tower Co. (NYSE:AMT)May 31 at 6:36 AM | americanbankingnews.comBarclays Cuts American Tower (NYSE:AMT) Price Target to $223.00May 30, 2024 | marketbeat.comFiduciary Trust Co Sells 4,107 Shares of American Tower Co. (NYSE:AMT)May 30, 2024 | marketbeat.comAmerican Tower (NYSE:AMT) PT Lowered to $223.00 at BarclaysMay 29, 2024 | marketbeat.comRoundview Capital LLC Grows Stock Position in American Tower Co. (NYSE:AMT)May 29, 2024 | businesswire.comJacksonville Transportation Authority Announces Groundbreaking of Autonomous Innovation Center (AIC) as Hub for U2C Program with Balfour Beatty's V2R TeamMay 29, 2024 | businesswire.comCoreSite Strengthens Native Cloud Ecosystem at Chicago Data Center Campus with AWS Direct ConnectMay 28, 2024 | marketbeat.comAmerican Tower Co. (NYSE:AMT) Shares Sold by Lockheed Martin Investment Management Co.May 28, 2024 | zacks.comHere's Why American Tower (AMT) Is an Apt Portfolio PickMay 27, 2024 | marketbeat.comProquility Private Wealth Partners LLC Invests $2.67 Million in American Tower Co. (NYSE:AMT)May 26, 2024 | marketbeat.comLinscomb & Williams Inc. Has $11.26 Million Stock Holdings in American Tower Co. (NYSE:AMT)May 25, 2024 | americanbankingnews.comAmerican Tower Co. (AMT) To Go Ex-Dividend on June 14thMay 24, 2024 | marketbeat.comNixon Peabody Trust Co. Has $9.91 Million Holdings in American Tower Co. (NYSE:AMT)May 24, 2024 | msn.comAmerican Tower declares $1.62 dividendMay 23, 2024 | marketbeat.comTeam Hewins LLC Takes Position in American Tower Co. (NYSE:AMT)May 23, 2024 | marketbeat.comAmerican Tower Co. (NYSE:AMT) to Issue Quarterly Dividend of $1.62May 23, 2024 | businesswire.comAmerican Tower Corporation Declares Quarterly DistributionMay 22, 2024 | marketbeat.comKing Luther Capital Management Corp Has $43.51 Million Stock Holdings in American Tower Co. (NYSE:AMT)New MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks You Can Buy Before They Become BigMay 6, 2024 8:00 AMView 3 Value Stocks You Can Buy Before They Become Big3 Stocks Nancy Pelosi Has Been BuyingMay 10, 2024 8:35 AMView 3 Stocks Nancy Pelosi Has Been Buying3 Affordable Stocks That Won’t Stay Down Much LongerMay 13, 2024 9:12 AMView 3 Affordable Stocks That Won’t Stay Down Much Longer3 Reasons Nvidia is on The Verge of a 4 Digit Stock PriceMay 17, 2024 8:39 AMView 3 Reasons Nvidia is on The Verge of a 4 Digit Stock Price3 Financial Stocks Outperforming as The Fed Dumps BondsMay 22, 2024 6:20 AMView 3 Financial Stocks Outperforming as The Fed Dumps BondsAll HeadlinesCompany DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American TowerNYSE:AMTAmerican Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
